The Third Circuit Rejects A Fraud Exception To The Noerr-Pennington Exemption From Antitrust Liability

The Third Circuit Court of Appeals held that Merck is exempt from antitrust claims under the Noerr-Pennington doctrine in a lawsuit accusing it of deceiving the government about the effectiveness of its mumps vaccine to prevent competition.

Background from the Third Circuit's Opinion

Merck was the sole licensed manufacturer of mumps vaccines in the United States for over fifty-five years, until 2022. The vaccine was FDA-approved and included an FDA-approved label that outlined its shelf life, minimum-potency requirements, and effectiveness. Merck had an ongoing duty to ensure that the drug label was accurate.

In the late 1990s, the FDA expressed concern that Merck's mumps vaccine did not provide immunity near the end of its purported 24-month shelf life. At the FDA's suggestion, Merck overfilled the vaccine doses to try to make the doses potent through the end of the shelf-life period.